Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

| More on:
Shot of a young scientist looking stressed out while working on a computer in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Telix Pharmaceuticals Ltd (ASX: TLX) shares are tumbling on Monday morning.

At the time of writing, the radiopharmaceuticals company's shares are down 8% to $26.35.

Why are Telix shares sinking?

Investors have been selling the company's shares today after it was dealt a blow from the US Food and Drug Administration (FDA).

According to the release, Telix has received a Complete Response Letter from the FDA for its New Drug Application (NDA) for TLX101-CDx (Pixclara). It is an investigational agent for the imaging of glioma, a rare and life-threatening brain cancer.

Telix advised that the CRL states that the FDA has completed its review of the application and has ruled that the NDA cannot be approved in its current form.

The regulator has stated that additional confirmatory clinical evidence is required to progress the application, despite a robust consultation process prior to submission and during review of the NDA.

One positive is that the FDA has not raised any concerns regarding product safety.

What next?

Telix will now request a hearing with the regulator to review the basis for the decision and is assessing clinical strategies available to augment the package in the near term.

The company described the news as "a disappointing outcome for American glioma patients."

It highlights that FET-PET is recommended medical best practice in relevant international oncology practice guidelines and is used extensively in other parts of the world. The company also points out that the FDA has granted TLX101-CDx Orphan Drug and Fast Track designation. It believes this is a tacit acknowledgement of the drug candidate's importance in addressing a significant unmet medical need and clinically demonstrating benefit over existing medical solutions.

Commenting on the news, Telix's managing director and CEO, Dr. Christian Behrenbruch, said:

We are committed to commercializing TLX101-CDx and fulfilling the unmet need to improve imaging to enable timelier and more accurate decisions for the clinical management of glioma. We have multiple go-forward pathways available to us, such as providing additional confirmatory data through several active clinical programs, including Company-led studies.

Our immediate focus is understanding the FDA's feedback and augmenting our submission with additional data to satisfy the Agency as soon as possible.

Despite this blow, there is no change to the company's financial guidance for 2025. That's because its guidance excludes revenue forecasts from unapproved products.

The company also advised that it remains committed to providing patient access to TLX101-CDx through the FDA-approved expanded access program.

Should you invest $1,000 in Netflix right now?

Before you buy Netflix shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Netflix wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX 200 stock crashing 30% today?

What's going with this stock? Let's find out why its shares are deep in the red.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »